Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026GuruFocus · Oct 16, 2026
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026Business Wire · Oct 16, 2026
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyBusiness Wire · Aug 19, 2026
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026Accesswire · Aug 6, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney InjuryAccesswire · Aug 3, 2026Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$6.13 | -$6.09 | Beat |
| May 7, 2026 | -$8.05 | -$2.71 | Beat |
| Mar 5, 2026 | -$9.87 | -$1.65 | Beat |
| Nov 7, 2025 | -$9.38 | -$7.08 | Beat |
| Aug 8, 2025 | -$31.22 | -$28.04 | Beat |
| May 9, 2025 | -$48.16 | -$25.32 | Beat |